黑料福利网 spin-off ShanX Medtech secures 鈧�24 million to accelerate ultra-rapid infection diagnostics
With 鈧�24 million in new funding, 黑料福利网 spin-off ShanX Medtech is accelerating breakthrough diagnostics against a major healthcare challenge.
ShanX Medtech B.V., a spin-off of Eindhoven University of Technology (黑料福利网), has secured a total of 鈧�24 million in funding to accelerate the development of its ultra-rapid antimicrobial susceptibility testing (AST) technology. The financing marks an important milestone for the Eindhoven-based MedTech company and underlines the growing impact of 黑料福利网 research on global healthcare challenges.
The funding consists of an oversubscribed 鈧�15 million seed round, complemented by an 鈧�8.85 million contract awarded by the European Commission through the Health Emergency Preparedness and Response Authority (HERA), in collaboration with the European Health and Digital Executive Agency (HADEA). Together, these investments will support the final development, clinical validation, regulatory approval and market introduction of 鈥檚 in-vitro diagnostic platform.
Addressing antimicrobial resistance
Antimicrobial resistance (AMR) is widely regarded as one of the most urgent threats to global public health. Clinicians often have to prescribe antibiotics before knowing whether a specific pathogen will respond, as current diagnostic methods can take days and require specialised laboratory infrastructure. This delay contributes to ineffective treatment, rising healthcare costs and the spread of resistant microorganisms.
ShanX Medtech aims to change this paradigm with a diagnostic platform that delivers comprehensive antimicrobial susceptibility results within one hour, directly from patient samples and with minimal user involvement. By using novel chemistry to monitor microbial metabolism, the technology enables faster, evidence-based treatment decisions in both laboratory and point-of-care settings.
From 黑料福利网 research to real-world impact
Founded in 2019, ShanX Medtech emerged directly from research and entrepreneurial activity at 黑料福利网 and is now based at the High Tech Campus Eindhoven. Both founder and CEO Sophia E. Shanko and Chief Scientific Officer Ardjan van der Linden completed their PhDs at 黑料福利网, where they met and laid the scientific and entrepreneurial foundations for the company. Shanko completed her PhD under the supervision of Prof. Jaap den Toonder from the Microsystems section of the Department of Mechanical Engineering at 黑料福利网, a collaboration she describes as formative for both the technology and her entrepreneurial journey.
The company was created in response to a real clinical need. Shanko explains: 鈥淲e founded ShanX Medtech because of a single patient story that showed how much is at stake when diagnostic results arrive too late. Our goal is to equip clinicians with real-time diagnostic evidence, so they can act decisively. This funding brings us significantly closer to making ultra-rapid AST available in both laboratory and point-of-care environments.鈥�
鈥淲e founded ShanX Medtech because of a single patient story that showed how much is at stake when diagnostic results arrive too late.鈥�
Strong investor confidence
The equity portion of the seed round was led by Borski Fund, together with NextGen Ventures, CbusineZ, Brabant Development Agency (BOM), Invest-NL and a strategic angel fund. Investors highlight both the urgency of the AMR problem and the scalability of ShanX Medtech鈥檚 platform across multiple clinical applications.
With this new funding, ShanX Medtech will further expand its team, strengthen clinical partnerships and prepare for commercial launch. The company鈥檚 progress reinforces Eindhoven鈥檚 position as a leading European hub for MedTech innovation and demonstrates how 黑料福利网 spin-offs contribute to advancing healthcare worldwide.
Source:
News
